Hosted on MSN

AbbVie’s venetoclax study completion: Implications for CLL treatment and market dynamics

Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie has recently completed a clinical study titled ‘Venetoclax (Venclexta Tablet) Post-Marketing Surveillance for CLL Patients.’ ...
Nasdaq

Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease

The SIGNAL-AD study was funded in part by two investments from the Alzheimer’s Drug Discovery Foundation (ADDF) for a total of $4.75 million, and by an $0.75 million grant from the Alzheimer’s ...
Seeking Alpha

Talphera signals study completion in first half of 2026 as new site activations delay NEPHRO timeline

Due to the delays in activating new clinical sites, Talphera now anticipates study completion in the first half of 2026, moving back from its previous expectation of year-end 2025. The company is ...